Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-NK 004
- Development stage
- Preclinical
- Lead developer
- ThinkingBiomed
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
CAR-NK 004 is an off-the-shelf, universal chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by ThinkingBiomed (also known as Xinchuan Biotechnology) for the treatment of solid tumors. The therapy is designed to target thoracic, digestive tract, urinary system, and reproductive system tumors. As an allogeneic, "off-the-shelf" cell therapy, it utilizes engineered natural killer cells to target and destroy cancer cells while minimizing the risk of graft-versus-host disease (GVHD) and cytokine release syndrome (CRS). CAR-NK 004 is currently in the early research and discovery stage.
Beyond the preview
Go deeper on CAR-NK 004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-NK 004.